Session: Crystallization of Pharmaceutical and Biological Molecules 1: In Honour of the Late Dr. Jeff Wei of Eli Lilly (2010 Annual Meeting)

Description:

This session welcomes papers addressing fundamental as well as applied studies in the area of crystallization of pharmaceutical or biological molecules. Topics related to experimental studies, theory and simulation that contribute to fundamental understanding of crystallization as well as industrial case studies on the crystallization development of pharmaceutical and biological compounds are encouraged.

Sponsor:

Pharmaceuticals

Co-Sponsor(s):

Crystallization and Evaporation (02B)

Chair:

Ryan C. Snyder
Bucknell University
Department of Chemical Engineering
Lewisburg, PA 17837
Phone Number: 570-577-2346
Email: ryan.snyder@bucknell.edu

Co-Chair:

Derek Griffin
Associate Senior Consultant Engineer
Lilly Research Laboratories, Eli Lilly and Company
Chemical Product Research and Development
Lilly Corporate Center
Indianapolis, IN 46285
Phone Number: 317-655-8804
Fax Number: 317-651-6510
Email: griffindw@lilly.com

Papers:

Introductory Remarks

88a

Development of a Direct Crystallization Process for a Highly Polymorphic API Compound
Brian P. Chekal, Pfizer Global Research & Development

88b

X-Ray Compatible Microfluidic Platforms for in Meso Crystallization of Membrane Proteins
Paul J. A. Kenis, University of Illinois at Urbana-Champaign; Sarah L. Perry, University of Illinois at Urbana-Champaign; Daria Khvostichenko, University of Illinois at Urbana-Champaign; Sudipto Guha, University of Illinois at Urbana-Champaign

88c

Crystallization Tendency of Active Pharmaceutical Ingredients and the Ability of Polymeric Additives to Alter Crystallization Behavior From Undercooled Melts
Jared Baird, Purdue University; Bernard Van Eerdenbrugh, Purdue University; Lynne Taylor, Purdue University

88d

Controlled Nucleation From Solution Using Polymer Microgels with Tunable Structure
Ying Diao, Massachusetts Institute of Technology; Matthew E. Helgeson, Massachusetts Institute of Technology; T. Alan Hatton, Massachusetts Institute of Technology; Patrick S. Doyle, Massachusetts Institute of Technology; Allan S. Myerson, Massachusetts Institute of Technology; Bernhardt L. Trout, Massachusetts Institute of Technology

88e

Determination of the Dynamic Metastable Zone Width for Lactose Crystallization
Shin Yee Wong, University of Wisconsin-Madison; Rajesh Bund, University of Wisconsin-Madison; Robin Connelly, Solae LLC; Richard W. Hartel, University of Wisconsin

88f

Process Modelling Tools for a Drown-out Crystallization Process Including Application to Scale-up
Eleftherios Kougoulos, Pfizer Inc

88g

Manufacturing Drug Substance That Meets Formulation Needs
Gerald Steele, AstraZeneca R&D Charnwood; Peter Morgan, AstraZeneca R&D Södertälje; Zhenyu Huang, AstraZeneca R&D Charnwood; Lee Griffiths, AstraZeneca R&D Charnwood; Sandra Gracin, AstraZeneca R&D Södertälje; Simon Black, AstraZeneca R&D Macclesfield; Frans Muller, AstraZeneca R&D Macclesfield; Claire Macleod, AstraZeneca R&D Macclesfield; Simon J. Lawton, AstraZeneca R&D Charnwood; Anne Kavanagh, AstraZeneca R&D Macclesfield

See more of this Group/Topical: Food, Pharmaceutical & Bioengineering Division

<< Previous Session | Next Session >>